| Size | Price | Stock | Qty |
|---|---|---|---|
| 250mg |
|
||
| Other Sizes |
| Targets |
Methoxypolyethylene glycol succinimidyl succinate does not have a defined biological target as a therapeutic agent. It is a PEGylation reagent used for the modification of proteins and peptides. The compound's utility lies in its ability to conjugate PEG chains to biomolecules, which can improve their pharmacokinetic properties, stability, and solubility. The succinimidyl ester group specifically targets primary amines on proteins.
|
|---|---|
| ln Vitro |
Specific in vitro activity data for Methoxypolyethylene glycol succinimidyl succinate as a pharmacological agent are not documented in the literature. It is a PEGylation reagent used in bioconjugation research. The compound's activity is assessed by its ability to react with primary amines and form stable amide bonds. Its effects on protein stability and activity are evaluated after conjugation.
|
| ln Vivo |
Methoxypolyethylene glycol succinimidyl succinate is not used for in vivo pharmacological activity assessment as a drug compound. It is a PEGylation reagent used for the modification of proteins and peptides. The compound is not intended to be administered as a therapeutic agent. PEGylated proteins, however, may be evaluated in vivo for their pharmacokinetic and pharmacodynamic properties.
|
| Enzyme Assay |
In vitro assays for Methoxypolyethylene glycol succinimidyl succinate typically involve assessing its reactivity with primary amines. The compound is incubated with a protein or peptide of interest, and the degree of PEGylation is determined by SDS-PAGE, mass spectrometry, or other analytical methods. The reaction is typically carried out in buffered solutions at pH 7.0-8.5. Standard bioconjugation protocols are employed for its use.
|
| Cell Assay |
Methoxypolyethylene glycol succinimidyl succinate is used in cell-based assays as a PEGylation reagent for modifying proteins that are subsequently tested in cell-based assays. The PEGylated proteins may be evaluated for their biological activity, stability, and cellular uptake. The compound itself is not characterized for direct cellular effects.
|
| Animal Protocol |
Methoxypolyethylene glycol succinimidyl succinate is not used directly in animal studies as a pharmacological agent. It is a PEGylation reagent used to modify proteins that may be administered to animals for pharmacokinetic or efficacy studies. The PEGylated proteins are evaluated for their circulation half-life, biodistribution, and therapeutic efficacy.
|
| ADME/Pharmacokinetics |
Methoxypolyethylene glycol succinimidyl succinate has a variable molecular weight depending on the PEG chain length. It is a white to off-white solid that is soluble in water and organic solvents. The compound is used as a PEGylation reagent for the modification of proteins and peptides. It is typically stored at -20°C, protected from moisture.
|
| Toxicity/Toxicokinetics |
Methoxypolyethylene glycol succinimidyl succinate is intended for research use only and is not approved for human therapeutic applications. As a research reagent, comprehensive toxicological data are not extensively documented in the publicly accessible literature. Standard safety precautions should be observed when handling this compound, including the use of appropriate personal protective equipment. The compound should be handled in well-ventilated areas with proper waste disposal procedures.
|
| Additional Infomation |
Methoxypolyethylene glycol succinimidyl succinate (mPEG-Succinimidyl Succinate) (CAS#: 78274-32-5) is a PEGylation reagent used for the modification of proteins, peptides, and other biomolecules. It reacts with primary amines to form stable amide bonds. This compound is not a drug and is a PEGylation reagent.
|
| Molecular Formula |
(C2H4O)NC9H11NO6
|
|---|---|
| Molecular Weight |
273.239303827286
|
| Exact Mass |
273.085
|
| CAS # |
78274-32-5
|
| Appearance |
Typically exists as solid at room temperature
|
| Melting Point |
56-60 °C
|
| SMILES |
O(C(CCC(COCCO)=O)=O)N1C(CCC1=O)=O
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.6598 mL | 18.2989 mL | 36.5979 mL | |
| 5 mM | 0.7320 mL | 3.6598 mL | 7.3196 mL | |
| 10 mM | 0.3660 mL | 1.8299 mL | 3.6598 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
